{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:18:06Z","timestamp":1779880686412,"version":"3.53.1"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":1095,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Sarcoma"],"published-print":{"date-parts":[[1997,1]]},"abstract":"<jats:p><jats:italic>Purpose<\/jats:italic>. This study investigates the efficacy and toxicity of daily oral etoposide in\nchemotherapy for non\u2010heavily pretreated advanced and metastatic soft tissue sarcoma (STS).<\/jats:p><jats:p><jats:italic>Subjects<\/jats:italic>. Twenty\u2010seven patients with progressive and measurable disease were treated. Median age was 53 years\n(range 20\u201371 years) and performance status WHO 0 or 1. Histologies included mainly leiomyosarcoma (8),\nmalignant fibrous histiocytoma (4), rhabdomyosarcoma (4), liposarcoma (2) and synovial sarcoma (2). Fifteen\npatients had received prior radiotherapy, of whom three included sites with haematopoiesis. All patients had received\nprior chemotherapy, including adjuvant therapy (7) and mostly consisted of one two\u2010drug schedule (ifosfamide and\ndoxorubicin) or two single\u2010drug regimens.<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>. Chemotherapy consisted of etoposide (VP16\u2010213), 50 mg m\u22122\nday\u22121 \u00d7 21 q 4 weeks. Blood cell counts\nwere done weekly. Dose reductions and a maximum delay of 2 weeks was allowed depending on cell counts during\ntreatment and at the start of a new 4\u2010week treatment cycle.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>. No objective response was observed. Progressive disease was observed after two treatment cycles in 17\/27\npatients (68%) and after three cycles in 22\/27 patients (81%). The other patients received three to five cycles.\nTwenty\u2010four patients went off study due to progressive disease. Grade 3 and 4 neutropenia was observed in eight\nand one patients, respectively. Thrombocytopenia grade 3 was seen in two patients. Non\u2010haematological toxicity\ngrade 3 (nausea, diarrhoea or alopecia) was observed in three patients, and grade 4 (dyspnea, hypotension or\nhaemorrhage) in three patients.<\/jats:p><jats:p><jats:italic>Discussion<\/jats:italic>. No objective response was obtained. Oral etoposide at a dose of 50 mg m\u22122\nday\u22121 \u00d7 21 q 4 weeks is\ninactive in chemotherapy of pretreated STS. Disease progression occurred within three cycles in the majority (81%)\nof patients. Toxicity of this regimen in non\u2010heavily pretreated patients is low.<\/jats:p>","DOI":"10.1080\/13577149778371","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T15:37:51Z","timestamp":1027697871000},"page":"99-101","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma"],"prefix":"10.1155","volume":"1","author":[{"given":"H. Jan","family":"Keizer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Steen","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan T. Van","family":"Oosterom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Hornedo","family":"Muguiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Van","family":"Pottelberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tursz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[1997,1]]},"container-title":["Sarcoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/sarcoma\/1997\/351365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/13577149778371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T18:46:21Z","timestamp":1723142781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/13577149778371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["10.1080\/13577149778371"],"URL":"https:\/\/doi.org\/10.1080\/13577149778371","archive":["Portico"],"relation":{},"ISSN":["1357-714X","1369-1643"],"issn-type":[{"value":"1357-714X","type":"print"},{"value":"1369-1643","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]},"assertion":[{"value":"1997-01-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}